Deng Shengxing: BeiGene is at a convergence point of three favorable factors.
鄧聲興:百濟神州正處三重利好交匯點
百濟神州(06160)集團正處於臨床數據兌現與全球化產能布局的雙重催化窗口——核心產品百悅澤(澤布替尼)在MCL一線治療
BeiGene (06160) Group is currently in a dual-catalyst window of opportunity: the realization of clinical data and the globalization of production capacity. Its core product, Baiyueze (Zanubrutinib), is a leading first-line treatment for MCL.